Orchid Pharma Q2 FY26 Earnings Call Transcript
Orchid Pharma's Q2 FY26 sales declined 13% YoY, but improved sequentially. Gross margins were impacted. The company completed the acquisition of Enmetazobactam global rights and expects licensing deals. Cefiderocol project is on track.
The acquisition of Enmetazobactam rights and progress on projects indicate potential for future growth, but current financial performance is under pressure, resulting in a medium impact.
The announcement discusses both positive developments (acquisition, project progress) and negative aspects (sales decline, margin compression), resulting in a neutral sentiment.
* Orchid Pharma held an earnings call on November 11, 2025, to discuss Q2 FY26 results. * Sales stood at ₹194 crore, a 13% year-on-year decline, but a 13% sequential improvement over Q1. * Gross margins were 32% compared to 43% in the previous quarter, impacted by weak market prices and increased sales in emerging markets with lower price realizations. * EBITDA for the quarter was ₹6 crore compared to ₹14 crore for the last quarter. * The company completed the acquisition of global rights to Enmetazobactam and the trademark Exblifep. * Exblifep has been licensed in Europe and MENA markets, with price approvals expected in the five largest EU markets by the end of the year. * Domestic demand for Orblicef continues to perform well, exceeding targets. * The 7ACA project is progressing, with fermenters erected and a target for mechanical completion announced earlier. * Cefiderocol project is on track for production readiness by Q4 of FY26. * The company expects to finalize licensing deals for Exblifep in new geographies and fast-track progress on projects. * Around 15,000 patients have been treated with Enmetazobactam in India, with over 200,000 vials sold. * The company is targeting potential deal for Enmetazobactam in the U.S. market in the next 12 months. * Dhanuka Labs merger is expected to be completed after the next hearing in the last week of November.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.